Heterozygous LDLR gene mutations were most prevalent when screening for autosomal dominant hypercholesterolemia in hypercholesterolemia patients and relatives from Norway.

This pooled patient-level analysis of three phase 3 trials (ORION-9, -10 and -11) shows that inclisiran reduces LDL-c on average by 50.7% compared to placebo in patients on maximally tolerated statin-therapy.

Experts in dialogue For which patients should combination therapy with statin and ezetimibe directly be initiated and for whom triple therapy with PCSK9 targeted therapy or bempedoic acid?

A meta-analysis of 5 trials showed that colchicine reduced MACE by 25% compared to placebo or no colchicine with a low between-trial heterogeneity in a wide range of patients with coronary disease.

This network meta-analysis of major bleeding outcomes in patients using NOACs or conventional therapy showed that the risk of major GI bleeding was reduced with apixaban and increased with rivaroxaban compared to warfarin.

The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.

This study validated six risk scores for ischemic stroke in patients with AF across the spectrum of kidney function. The Modified CHADS2 score showed most consistent predictive performance in all kidney function categories.

Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.

This subanalysis of the POPular Genetics trial showed that non-carriers of CYP2C19*2 or *3 LoF alleles treated with clopidogrel after primary PCI had less bleeding and similar thrombotic risk compared to patients on ticagrelor or prasugrel.

Danny Claassens presents the results of a prespecified subanalysis of the POPular Genetics trial, which focused on trombotic and bleeding outcomes in CYP2C19 genotype subgroups treated with clopidogrel or standard ticagrelor/prasugrel after PCI.

Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.